Poly (ADP-ribose) polymerase (PARP) inhibitors have markedly improved progression-free survival in BRCA-mutated and homologous recombination deficiency (HRD)-positive patients. This evidence concerns the gene PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome.